Cover Image
市場調查報告書

纖維肌痛症:全球臨床實驗趨勢

Fibromyalgia Global Clinical Trials Review, H2, 2017

出版商 GlobalData 商品編碼 167050
出版日期 內容資訊 英文 224 Pages
訂單完成後即時交付
價格
Back to Top
纖維肌痛症:全球臨床實驗趨勢 Fibromyalgia Global Clinical Trials Review, H2, 2017
出版日期: 2017年08月23日 內容資訊: 英文 224 Pages
簡介

本報告提供纖維肌痛症相關臨床研究之最新趨勢分析,提供您疾病·治療方法概要,及G7與E7各國的臨床實驗狀況,各地區、各階段的進行狀況,有潛力的贊助商,各企業及研究機關的研究進行狀況,有潛力的藥劑比較等資訊。

本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 前五名國家的臨床實驗數量; 亞太地區
    • 前五名國家的臨床實驗數量; 歐洲
    • 主要國家的臨床實驗數量; 北美
    • 主要國家的臨床實驗數量; 中東/非洲地區
    • 前五名國家的臨床實驗數量; 中南美

G7各國的臨床實驗數量:纖維肌痛症臨床實驗數量佔中樞神經系統臨床實驗數量比率

Phase別臨床實驗數量: G7各國

G7各國的臨床實驗數量:Phase別

E7各國的臨床實驗數量:纖維肌痛症臨床實驗數量佔中樞神經系統臨床實驗數量比率

Phase別臨床實驗數量: E7各國

E7各國的臨床實驗數量:Phase別

Phase別臨床實驗數量

  • Phase別的進展中臨床實驗數量

各進展狀況臨床實驗數量

評估項目別臨床實驗數量

一定期間所採用的受驗人數

贊助商類別的臨床實驗數量

有潛力的贊助商

臨床實驗主要參加企業 - 纖維肌痛症治療藥

有潛力的藥劑

最新臨床實驗新聞:纖維肌痛症

臨床實驗簡介的基本資料

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4477CTIDB

GlobalData's clinical trial report, "Fibromyalgia Global Clinical Trials Review, H2, 2017" provides an overview of Fibromyalgia clinical trials scenario. This report provides top line data relating to the clinical trials on Fibromyalgia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 14
  • Top Five Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Fibromyalgia to Central Nervous System Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Fibromyalgia to Central Nervous System Clinical Trials 19
  • Clinical Trials by Phase in E7 Countries 20
  • Clinical Trials in E7 Countries by Trial Status 21
  • Clinical Trials by Phase 22
  • In Progress Trials by Phase 23
  • Clinical Trials by Trial Status 24
  • Clinical Trials by End Point Status 25
  • Subjects Recruited Over a Period of Time 26
  • Clinical Trials by Sponsor Type 27
  • Prominent Sponsors 28
  • Top Companies Participating in Fibromyalgia Therapeutics Clinical Trials 30
  • Prominent Drugs 32
  • Latest Clinical Trials News on Fibromyalgia 33
  • Aug 01, 2017: Aptinyx Initiates Phase 2 Clinical Studies Evaluating NYX-2925 in Two Chronic Pain Conditions 33
  • Jun 30, 2017: Daiichi Sankyo Announces Top-line Results from Phase 3 Global Clinical Development Program Evaluating Mirogabalin in Pain Syndromes 33
  • Jun 26, 2017: Zynerba Pharmaceuticals Initiates ZYN001 Phase 1 Clinical Program 34
  • Clinical Trial Profile Snapshots 35

Appendix 222

  • Abbreviations 222
  • Definitions 222
  • Research Methodology 223
  • Secondary Research 223
  • About GlobalData 224
  • Contact Us 224
  • Source 224

List of Tables

List of Tables

  • Fibromyalgia Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Fibromyalgia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Fibromyalgia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Fibromyalgia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
  • Fibromyalgia Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
  • Fibromyalgia Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
  • Fibromyalgia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 14
  • Fibromyalgia Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 15
  • Proportion of Fibromyalgia to Central Nervous System Clinical Trials, G7 Countries (%), 2017* 16
  • Fibromyalgia Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Fibromyalgia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Fibromyalgia to Central Nervous System Clinical Trials, E7 Countries (%), 2017* 19
  • Fibromyalgia Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
  • Fibromyalgia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Fibromyalgia Therapeutics, Global, Clinical Trials by Phase, 2017* 22
  • Fibromyalgia Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23
  • Fibromyalgia Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
  • Fibromyalgia Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
  • Fibromyalgia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
  • Fibromyalgia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 27
  • Fibromyalgia Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 29
  • Fibromyalgia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 31
  • Fibromyalgia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32

List of Figures

List of Figures

  • Fibromyalgia Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
  • Fibromyalgia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Fibromyalgia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Fibromyalgia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
  • Fibromyalgia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
  • Fibromyalgia Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
  • Fibromyalgia Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 14
  • Fibromyalgia Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 15
  • Proportion of Fibromyalgia to Central Nervous System Clinical Trials, G7 Countries (%), 2017* 16
  • Fibromyalgia Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Fibromyalgia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Fibromyalgia to Central Nervous System Clinical Trials, E7 Countries (%), 2017* 19
  • Fibromyalgia Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
  • Fibromyalgia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Fibromyalgia Therapeutics, Global, Clinical Trials by Phase (%), 2017* 22
  • Fibromyalgia Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 23
  • Fibromyalgia Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
  • Fibromyalgia Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
  • Fibromyalgia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
  • Fibromyalgia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 27
  • Fibromyalgia Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
  • Fibromyalgia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 30
  • Fibromyalgia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32
  • GlobalData Methodology 223
Back to Top